News
-
-
-
-
PRESS RELEASE
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Napo Pharmaceuticals enters extension phase with blinded doses of crofelemer to support NDA filing for ultrarare pediatric disease MVID in mid-2027 -
-
PRESS RELEASE
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Jaguar Health, Inc. launches Neonorm Dog on Amazon, expanding Neonorm franchise to support dogs' GI health with plant-based product. Available soon on Chewy -
-
-
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research published an update on Jaguar Health Inc, maintaining an 'UNDER REVIEW' rating and price target. Q2/26 results in line with expectations, strategic transformations noted, and balance sheet strengthened